嘉和生物-B(06998)今日盘中大涨5.11%，表现强劲。
消息面上，嘉和生物药业（开曼）控股有限公司已通过港交所上市聆讯。根据招股书，嘉和生物主要从事肿瘤及自体免疫药物的开发及商业化，产品管线覆盖乳腺癌、肺癌及胃肠道肿瘤等全球前三大肿瘤靶标。此次通过聆讯标志着公司向上市迈出了关键一步，增强了市场对其发展前景的信心。
值得注意的是，嘉和生物此次上市是通过反向并购亿腾医药集团有限公司的方式完成，交易完成后公司将更名为“亿腾嘉和医药集团有限公司”。这将是香港首宗依据《上市规则》第18A章的未盈利生物科技公司反向并购案例，具有里程碑意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.